M&A Deal Summary

ICON Acquires BeijingWits Medical Consulting

On December 12, 2011, ICON acquired life science company BeijingWits Medical Consulting

Acquisition Highlights
  • This is ICON’s 9th transaction in the Life Science sector.
  • This is ICON’s 1st transaction in China.

M&A Deal Summary

Date 2011-12-12
Target BeijingWits Medical Consulting
Sector Life Science
Buyer(s) ICON
Deal Type Add-on Acquisition

Target

BeijingWits Medical Consulting

China
BeijingWits Medical Consulting Ltd. is a provider of services to global and local pharmaceutical, medical device and biotechnology companies focusing on Phase I to IV Clinical studies.

Search 193,448 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

ICON

Dublin, Ireland

website


Category Company
Founded 1990
Sector Life Science
Employees38,330
DESCRIPTION

ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development – from compound selection to Phase I-IV clinical studies. ICON was founded in 1990 and is based in Dublin, Ireland.


DEAL STATS #
Overall 17 of 29
Sector (Life Science) 9 of 16
Type (Add-on Acquisition) 14 of 25
Country (China) 1 of 1
Year (2011) 3 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2011-07-14 Firecrest Clinical

Limerick, Ireland

Firecrest Clinical Ltd. is a provider of technology solutions that boost investigator site performance and study management. Firecrest definitively improves clinical site performance through e-clinical technology solutions that provide investigator training and study management tools.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2012-02-28 PriceSpective

London, United Kingdom

PriceSpective Ltd. is a value strategy consultancy that defines, drives, and captures value for pharmaceutical and biotechnology clients in today’s complex healthcare environment. The company delivers expert guidance in integrated global pricing, reimbursement and market access strategy with its depth of experience and actively engaged senior leadership.

Buy -